TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...